Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor.[3] It is taken by mouth.[3]
Compared with warfarin it has fewer drug interactions.[6]
It was developed by Daiichi Sankyo and approved in July 2011, in Japan for prevention of venous thromboembolisms following lower-limb orthopedic surgery.[7] It was also approved in the United States by the Food and Drug Administration (FDA) in January 2015, for the prevention of stroke and non–central-nervous-system systemic embolism.[8][9] It was approved for use in the European Union in June 2015.[4] It is on the World Health Organization's List of Essential Medicines.[10]
^"Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
^"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ abc"Savaysa- edoxaban tosylate tablet, film coated". DailyMed. 24 April 2020. Retrieved 23 July 2020.
^ abCite error: The named reference Lixiana EPAR was invoked but never defined (see the help page).
^"Roteas EPAR". European Medicines Agency (EMA). Retrieved 25 September 2020.
^ abcdeParasrampuria DA, Truitt KE (June 2016). "Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting FactorXa". Clinical Pharmacokinetics. 55 (6): 641–55. doi:10.1007/s40262-015-0342-7. PMC 4875962. PMID 26620048.
^"First market approval in Japan for Lixiana (Edoxaban)". Daiichi Sankyo Europe GmbH (Press release). 22 April 2011. Archived from the original on 6 November 2013.
^O'Riordan M (9 January 2015). "FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE Prevention". Medscape. Retrieved 10 January 2015.
^"Drug Approval Package: Savaysa (edoxaban tosylate) Tablets NDA #206316". U.S. Food and Drug Administration (FDA). 13 February 2015. Retrieved 23 July 2020.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor. It is taken by mouth. Compared...
clotting) drugs, including factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), dabigatran, and heparins (including fondaparinux, low molecular weight...
(dabigatran) and factor Xa inhibitor (rivaroxaban, apixaban, betrixaban and edoxaban), and they have been shown to be as good or possibly better than the coumarins...
beta; and their quality-assured biosimilars are alternatives Apixaban, edoxaban, and rivaroxaban are alternatives Alternatives are dalteparin and nadroparin...
Rivaroxaban competes with other newer generation anticoagulants such as edoxaban, apixaban, and dabigatran as well as with the generic anticoagulant warfarin...
(co-marketed with Eli Lilly and Company; also sold as Efient) Lixiana/Savaysa (edoxaban) Minnebro (esaxerenone) (available only in Japan) Nilemdo (bempedoic acid...
intracerebral brain hemorrhage, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. Dabigatran is contraindicated in patients who have active...
directly acting oral anticoagulants: dabigatran, rivaroxaban, apixaban, and edoxaban). Theories on the coagulation of blood have existed since antiquity. Physiologist...
symptomatic heart failure. Apixaban and other anticoagulants (dabigatran, edoxaban and rivaroxaban) appear equally effective as warfarin in preventing non-hemorrhagic...
dabigatran and edoxaban do. A Cochrane review found that there is no evidence of a difference between oral DTIs (dabigatran, rivaroxaban, edoxaban, apixaban)...
fibrillation (AF). Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning...
oral anticoagulants (DOACs) such as dabigatran, apixaban, rivaroxaban and edoxaban from blood plasma samples. For this purpose it has been made into "minitablets"...
suggested for edoxaban, but use of it is considered off label due to limited evidence. A reversal agent for dabigatran, apixaban, edoxaban, and rivaroxaban...
specifically direct oral anticoagulants (i.e. dabigatran, apixaban, rivaroxaban, edoxaban) and vitamin K antagonists (i.e. warfarin), are very effective in lowering...
drugs rivaroxaban, apixaban, betrixaban, LY517717, darexaban (YM150), edoxaban and 813893. These agents have several theoretical advantages over current...
(a factor Xa inhibitor), dabigatran (a direct thrombin inhibitor), and edoxaban (a factor Xa inhibitor). Other anticoagulants cannot be taken by mouth...
through several means including warfarin, heparin, dabigatran, rivaroxaban, edoxaban, and apixaban. Many issues should be considered related to their comparative...
approved in Europe in 2011 and in the United States in 2012. The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the...
clots from forming) with the DOACs dabigatran, rivaroxaban, apixaban, or edoxaban rather than warfarin or low molecular weight heparin (LMWH). For those...
injected daily. Rivaroxaban, Apixaban and Edoxaban are direct factor Xa inhibitors. Rivaroxaban, Apixaban and Edoxaban bind to the active site of factor Xa...
pregnant women. Currently, rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) are DOACs listed under Pregnancy Category C, and apixaban (Eliquis)...
to concerns of increased bleeding risk and absence of reversal agent. Edoxaban Enoxaparin Eriksson BI, Quinlan DJ, Weitz JI (2009). "Comparative pharmacodynamics...
Administration (FDA): dabigatran (thrombin inhibitor), apixaban, rivaroxaban, edoxaban (all factor Xa inhibitors). In the United Kingdom, the NICE guidelines...
Global Information
(what is this?) (verify)